Effects of Serum PSA on Efficacy of Tolterodine Extended Release With or Without Tamsulosin in Men With LUTS, Including OAB

Urology

Volumn 72, Issue 5, 2008, Pages 1061-1067

  Roehrborn, Claus G ^a   Kaplan, Steven A ^b   Kraus, Stephen R ^c   Wang, Joseph T ^d   Bavendam, Tamara ^d   Guan, Zhonghong ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN; TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION; OVERACTIVE BLADDER; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BENZHYDRYL COMPOUNDS; COHORT STUDIES; CRESOLS; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; SULFONAMIDES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINATION DISORDERS;

EID: 54449099907     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.06.067     Document Type: Article

References (30)

1. Chapple C.R., and Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49 (2006) 651-659
2. Peters T.J., Donovan J.L., Kay H.E., et al. The International Continence Society "Benign Prostatic Hyperplasia" study: The bothersomeness of urinary symptoms. J Urol 157 (1997) 885-889
3. Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 50 (2006) 1306-1315
4. Andersson K.E. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol 3 (2004) 46-53
5. Abrams P., Kaplan S.A., De Koning Gans H.J., et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175 (2006) 999-1004
6. Kaplan S.A., Walmsley K., and Te A.E. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174 (2005) 2273-2276
7. Kaplan S., Roehrborn C., Dmochowski R., et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 68 (2006) 328-332
8. Roehrborn C.G., Abrams P., Rovner E.S., et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 97 (2006) 1003-1006
9. Kaplan S.A., Roehrborn C.G., Rovner E.S., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial. JAMA 296 (2006) 2319-2328
10. Blake-James B.T., Rashidian A., Ikeda Y., et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. BJU Int 99 (2007) 85-96
11. Dmochowski R., Abrams P., Marschall-Kehrel D., et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 51 (2007) 1054-1064
12. Roehrborn C.G., Boyle P., Gould A.L., et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53 (1999) 581-589
13. Roehrborn C.G., McConnell J., Bonilla J., et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia: Proscar Long-term Efficacy and Safety Study. J Urol 163 (2000) 13-20
14. Roehrborn C.G., Boyle P., Bergner D., et al., PLESS Study Group. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: Results of a four-year, randomized trial comparing finasteride versus placebo. Urology 54 (1999) 662-669
15. Crawford E.D., Wilson S.S., McConnell J.D., et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175 (2006) 1422-1427
16. St. Sauver J.L., Jacobson D.J., Girman C.J., et al. Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort. J Urol 175 (2006) 1018-1022
17. Bruskewitz R., Girman C.J., Fowler J., et al., Proscar Long-Term Efficacy and Safety Study (PLESS) Study Group. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. Urology 54 (1999) 670-678
18. Roehrborn C.G., Malice M., Cook T.J., et al. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: A comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 58 (2001) 210-216
19. Roehrborn C.G., McConnell J.D., Saltzman B., et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 42 (2002) 1-6
20. Hayward R.A., Kent D.M., Vijan S., et al. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol 6 (2006) 18
21. Kent D.M., and Hayward R.A. Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification. JAMA 298 (2007) 1209-1212
22. Mochtar C.A., Kiemeney L.A., van Riemsdijk M.M., et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 44 (2003) 695-700
23. O'Leary M.P., Roehrborn C., Andriole G., et al. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor. BJU Int 92 (2003) 262-266
24. Coyne KS, Matza L, Thompson C, et al. A comparison of three approaches to analyze urinary urgency as a treatment outcome. Presented at 35th Annual Meeting of the International Continence Society, August 28-September 2, 2005, Montreal, Quebec, Canada.
25. Coyne KS, Matza L, Thompson C, et al. From an OAB patient perspective: Health-related quality of life improves when frequency and urgency improve. Presented at 35th Annual Meeting of the International Continence Society, August 28-September 2, 2005, Montreal, Quebec, Canada.
26. Kaplan S.A., Roehrborn C.G., Dmochowski R., et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 68 (2006) 328-332
27. Milani S., and Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Latest update on alpha-adrenoceptor antagonists. BJU Int 95 suppl 4 (2005) 29-36
28. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
29. Roehrborn C.G., McConnell J.D., Lieber M., et al., PLESS Study Group. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 53 (1999) 473-480
30. Trueman P., Hood S.C., Nayak U.S., et al. Prevalence of lower urinary tract symptoms and self-reported diagnosed "benign prostatic hyperplasia," and their effect on quality of life in a community-based survey of men in the UK. BJU Int 83 (1999) 410-415